文献速递炎症性肠病

炎症性肠病患者感染SARS-CoV-2后2周内输注生物制剂对病程的影响

Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-25

本文旨在探讨炎症性肠病(IBD)患者感染SARS-CoV-2后1-2周内输注生物制剂对临床病程的影响,指出该领域尚未被探索且患者可能因延迟治疗而影响病情,但摘要未报告具体研究设计与结果。

要点

  • 研究目的是评估IBD患者感染SARS-CoV-2后1-2周内给予生物制剂对临床病程的影响。
  • 作者指出该问题尚未被探索,且患者可能延迟预定治疗从而对临床状况产生不利影响。

核心结论

  • 原文未报告研究结论。

研究设计与样本

  • 原文未报告研究设计与样本量。

主要发现

  • 原文未报告研究结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 was first identified in Wuhan in December 2019 and since then it has progressed into a pandemic that evolves continuously.1 As of May 5, 2022, there have been more than 81 million cases and 994,187 deaths in the United States.2 Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract consisting of ulcerative colitis and Crohn's disease treated with immunosuppressive/immunomodulatory agents. Over the course of the pandemic different aspects of the interaction between SARS-COV-2 and IBD medications have been studied.3,4 At the onset of the pandemic there was decreased use of infusible biologics.5 Despite the passage of time an area that has not been explored is the impact of biologics on the clinical course of SARS-COV-2 when given soon after the detection of infection. Our aim was to determine the impact of biologics on the clinical course of SARS-COV-2 among patients with IBD, when given 1-2 weeks postinfection among stable patients. This is of critical importance because patients may delay getting their scheduled treatment, which in turn could adversely affect their clinical condition.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Khan N, Patel M, Sundararajan R, et al. Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients. Clin Gastroenterol Hepatol. 2022. PMID: 36029967. doi:10.1016/j.cgh.2022.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。